Acneiform rash from targeted cancer therapies
An acneiform rash (papulopustular eruption) is common in patients treated with epidermal growth factor receptor (EGFR) inhibitors, including tyrosine kinase inhibitors and monoclonal antibodies. Appearance of the rash correlates with response to treatment. The rash may also be accompanied by bacterial colonisation or infection.
Most cases of acneiform rash are mild and can be treated with a topical therapy (corticosteroid or antibiotic) and consideration of oral antibiotics. Severe cases may require stopping anticancer therapy, and treatment with systemic corticosteroids and antibioticsLacouture, 2021. For more information on management of acneiform rash associated with EGFR inhibitors, see the eviQ website.